Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation
Age and Ageing · 03.08.2026 · 55 (8)
DOI: 10.1093/ageing/afag246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Age and Ageing, online erschienen am 19.08.2026. Verfasst von Hisashi Noma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interdisciplinary Statistical Mathematics, The Institute of Statistical Mathematics, Tachikawa, Tokyo, Japan. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular and renal outcomes, but evidence in adults aged ≥75 years remains limited, particularly compared with dipeptidyl peptidase-4 inhibitors (DPP-4i).
Methods
We conducted a target trial emulation using linked administrative claims and health examination data in Japan. Individuals aged ≥75 years with type 2 diabetes who newly initiated an SGLT2i or DPP-4i were identified. Intention-to-treat (ITT) effects were estimated using inverse probability weighting, with a 1-month induction period for mortality, cardiovascular and renal outcomes.
Results
The study included 8486 individuals (2204 SGLT2i users, 6282 DPP-4i users). After a 1-month induction period, SGLT2i initiation was associated with lower all-cause mortality (hazard ratio [HR] 0.677, 95% confidence interval [CI] 0.500–0.916) and lower risk of end-stage renal disease or dialysis (HR 0.374, 95% CI 0.157–0.890). No clear differences were observed for heart failure hospitalisation (HR 1.103, 95% CI 0.854–1.426) or myocardial infarction (HR 1.015, 95% CI 0.768–1.341) in the ITT analysis. Stroke occurred more frequently among SGLT2i users (HR 1.420, 95% CI 1.165–1.828), although this finding should be interpreted cautiously.
Conclusions
Among adults aged ≥75 years with type 2 diabetes, SGLT2i initiation was associated with lower all-cause mortality and renal risk compared with DPP-4i initiation. The higher observed stroke risk requires cautious interpretation because residual confounding, competing mortality and heterogeneity in vulnerable older adults may contribute to this signal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interdisciplinary Statistical Mathematics, The Institute of Statistical Mathematics, Tachikawa, Tokyo, Japan.
- The Graduate Institute for Advanced Studies, The Graduate University for Advanced Studies (SOKENDAI), Tachikawa, Tokyo, Japan.
- Advanced Medicine, Innovation and Clinical Research Center, Tottori University Hospital, Yonago, Tottori, Japan.
- Department of Public Health, School of Medicine, Association of Medical Science, Yokohama City University, Yokohama, Kanagawa, Japan.
- Department of Prevention and Care Science, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
- Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
ORCID-Profile: Hisashi Noma, Atsushi Goto, Taiki Sugimoto
Zitieren
APA
Noma, H., Goto, A., Sugimoto, T., Sunada, H., Oda, F., Maeda, M., & Fukuda, H. (2026). Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation. Age and Ageing, 55(8). https://doi.org/10.1093/ageing/afag246
Vancouver
Noma H, Goto A, Sugimoto T, Sunada H, Oda F, Maeda M, et al. Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation. Age and Ageing. 2026;55(8). doi:10.1093/ageing/afag246
BibTeX
@article{Noma2026,
author = {Noma, Hisashi and Goto, Atsushi and Sugimoto, Taiki and Sunada, Hiroshi and Oda, Futoshi and Maeda, Megumi and Fukuda, Haruhisa},
title = {Real-world effectiveness of SGLT2 inhibitors in adults aged 75 years or older: a target trial emulation},
journal = {Age and Ageing},
year = {2026},
volume = {55},
number = {8},
doi = {10.1093/ageing/afag246}
}
EUVIMED